Sentiment-Signal
21,3
Stark Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Stammdaten
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
Unternehmen & Branche
| Name | PTC THERAPEUTICS, INC. |
|---|---|
| Ticker | PTCT |
| CIK | 0001070081 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 5,32 Mrd. USD |
| Beta | 0,55 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 1,730,655,000 | 682,644,000 | 7.78 | 2,898,767,000 | -205,313,000 |
| 2025-09-30 | 10-Q | 211,007,000 | 15,896,000 | 0.20 | 2,643,700,000 | -155,758,000 |
| 2025-06-30 | 10-Q | 178,875,000 | -64,849,000 | -0.83 | 2,634,155,000 | -206,546,000 |
| 2025-03-31 | 10-Q | 1,176,096,000 | 866,562,000 | 10.04 | 2,655,387,000 | -185,760,000 |
| 2024-12-31 | 10-K | 806,780,000 | -363,295,000 | -4.73 | 1,705,024,000 | -1,098,071,000 |
| 2024-09-30 | 10-Q | 196,786,000 | -106,654,000 | -1.39 | 1,842,236,000 | -1,054,352,000 |
| 2024-06-30 | 10-Q | 186,704,000 | -99,179,000 | -1.29 | 1,916,355,000 | -980,181,000 |
| 2024-03-31 | 10-Q | 210,118,000 | -91,576,000 | -1.20 | 1,789,629,000 | -893,916,000 |
| 2023-12-31 | 10-K | 937,822,000 | -626,604,000 | -8.37 | 1,895,698,000 | -818,555,000 |
| 2023-09-30 | 10-Q | 196,576,000 | -132,970,000 | -1.76 | 1,259,885,000 | -670,810,000 |
| 2023-06-30 | 10-Q | 213,808,000 | -198,883,000 | -2.66 | 1,338,124,000 | -579,268,000 |
| 2023-03-31 | 10-Q | 220,382,000 | -138,959,000 | -1.88 | 1,608,839,000 | -457,561,000 |
| 2022-12-31 | 10-K | 698,801,000 | -559,017,000 | -7.79 | 1,705,619,000 | -347,086,000 |
| 2022-09-30 | 10-Q | 217,127,000 | -109,315,000 | -1.53 | 1,576,398,000 | -226,904,000 |
| 2022-06-30 | 10-Q | 165,526,000 | -152,087,000 | -2.13 | 1,804,057,000 | -182,218,000 |
| 2022-03-31 | 10-Q | 148,735,000 | -126,726,000 | -1.78 | 1,799,591,000 | -90,581,000 |
| 2021-12-31 | 10-K | 538,593,000 | -523,901,000 | -7.43 | 1,938,056,000 | 1,438,000 |
| 2021-09-30 | 10-Q | 138,743,000 | -133,624,000 | -1.89 | 2,007,325,000 | 104,926,000 |
| 2021-06-30 | 10-Q | 116,676,000 | -118,370,000 | -1.68 | 2,058,669,000 | 196,577,000 |
| 2021-03-31 | 10-Q | 117,942,000 | -128,642,000 | -1.83 | 2,111,941,000 | 292,576,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-21 | Klein Matthew B. | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -2,850 | 70.91 | -202,093.50 | -80,7% | |
| 2026-04-02 | Golden Lee Scott | Officer, EVP & CHIEF MEDICAL OFFICER | Open Market Sale | -829 | 67.99 | -56,363.71 | -22,5% | |
| 2026-03-12 | Klein Matthew B. | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -2,662 | 64.08 | -170,580.96 | -68,2% | |
| 2026-03-10 | Okey Stephanie | Director | Open Market Sale | -14,000 | 70.00 | -980,000.00 | -391,5% | |
| 2026-03-10 | Okey Stephanie | Director | Open Market Sale | -1,167 | 70.00 | -81,690.00 | -32,6% | |
| 2026-03-05 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -3,989 | 63.38 | -252,822.82 | -101,0% | |
| 2026-03-05 | Golden Lee Scott | Officer, EVP & CHIEF MEDICAL OFFICER | Open Market Sale | -10,000 | 63.38 | -633,800.00 | -253,2% | |
| 2026-03-05 | Okey Stephanie | Director | Open Market Sale | -6,333 | 63.38 | -401,385.54 | -160,4% | |
| 2026-02-19 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -588 | 68.54 | -40,301.52 | -16,1% | |
| 2026-02-19 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -1,629 | 69.82 | -113,736.78 | -45,4% | |
| 2026-02-19 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -590 | 69.82 | -41,193.80 | -16,5% | |
| 2026-02-19 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -212 | 68.54 | -14,530.48 | -5,8% | |
| 2026-02-18 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -3,081 | 69.36 | -213,698.16 | -85,4% | |
| 2026-02-18 | Klein Matthew B. | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -7,371 | 69.36 | -511,252.56 | -204,3% | |
| 2026-02-18 | Golden Lee Scott | Officer, EVP & CHIEF MEDICAL OFFICER | Open Market Sale | -2,484 | 69.36 | -172,290.24 | -68,8% | |
| 2026-02-18 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -3,056 | 69.36 | -211,964.16 | -84,7% | |
| 2026-02-18 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -65 | 69.36 | -4,508.40 | -1,8% | |
| 2026-02-18 | Pauwels Eric | Officer, CHIEF BUSINESS OFFICER | Open Market Sale | -3,019 | 69.36 | -209,397.84 | -83,7% | |
| 2026-02-18 | Gravier Pierre | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -2,992 | 69.36 | -207,525.12 | -82,9% | |
| 2026-02-18 | Utter Christine Marie | Officer, SVP, CHIEF ACCOUNTING OFFICER | Open Market Sale | -2,494 | 69.36 | -172,983.84 | -69,1% | |
| 2026-02-17 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -2 | 70.13 | -140.26 | -0,1% | |
| 2026-02-17 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -2,811 | 69.29 | -194,774.19 | -77,8% | |
| 2026-01-12 | Pauwels Eric | Officer, CHIEF BUSINESS OFFICER | Open Market Sale | -1,024 | 78.70 | -80,588.80 | -32,2% | |
| 2026-01-09 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -1,521 | 77.46 | -117,816.66 | -47,1% | |
| 2026-01-09 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -107 | 79.52 | -8,508.64 | -3,4% | |
| 2026-01-09 | Pauwels Eric | Officer, CHIEF BUSINESS OFFICER | Open Market Sale | -1,722 | 77.41 | -133,300.02 | -53,3% | |
| 2026-01-09 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -686 | 78.71 | -53,995.06 | -21,6% | |
| 2026-01-08 | Utter Christine Marie | Officer, SVP, CHIEF ACCOUNTING OFFICER | Open Market Sale | -1,034 | 76.45 | -79,049.30 | -31,6% | |
| 2026-01-08 | Golden Lee Scott | Officer, EVP & CHIEF MEDICAL OFFICER | Open Market Sale | -866 | 76.45 | -66,205.70 | -26,5% | |
| 2026-01-08 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -881 | 76.45 | -67,352.45 | -26,9% | |
| 2026-01-08 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -59 | 76.45 | -4,510.55 | -1,8% | |
| 2026-01-08 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -2,482 | 76.56 | -190,021.92 | -75,9% | |
| 2026-01-08 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -1,286 | 76.45 | -98,314.70 | -39,3% | |
| 2026-01-08 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -265 | 77.07 | -20,423.55 | -8,2% | |
| 2026-01-08 | Pauwels Eric | Officer, CHIEF BUSINESS OFFICER | Open Market Sale | -2,561 | 76.42 | -195,711.62 | -78,2% | |
| 2026-01-08 | Pauwels Eric | Officer, CHIEF BUSINESS OFFICER | Open Market Sale | -1,454 | 76.45 | -111,158.30 | -44,4% | |
| 2026-01-08 | Pauwels Eric | Officer, CHIEF BUSINESS OFFICER | Open Market Sale | -587 | 76.98 | -45,187.26 | -18,1% | |
| 2026-01-08 | Klein Matthew B. | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -2,514 | 76.45 | -192,195.30 | -76,8% | |
| 2026-01-07 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -269 | 77.92 | -20,960.48 | -8,4% | |
| 2026-01-07 | Golden Lee Scott | Officer, EVP & CHIEF MEDICAL OFFICER | Open Market Sale | -642 | 77.48 | -49,742.16 | -19,9% | |
| 2026-01-07 | Klein Matthew B. | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -3,016 | 77.48 | -233,679.68 | -93,4% | |
| 2026-01-07 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -1,026 | 77.48 | -79,494.48 | -31,8% | |
| 2026-01-07 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -52 | 77.48 | -4,028.96 | -1,6% | |
| 2026-01-07 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -1,638 | 77.11 | -126,306.18 | -50,5% | |
| 2026-01-07 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -1,503 | 77.48 | -116,452.44 | -46,5% | |
| 2026-01-07 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -949 | 77.91 | -73,936.59 | -29,5% | |
| 2026-01-07 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -471 | 77.10 | -36,314.10 | -14,5% | |
| 2026-01-07 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -38 | 78.60 | -2,986.80 | -1,2% | |
| 2026-01-07 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -11 | 78.98 | -868.78 | -0,3% | |
| 2026-01-07 | Pauwels Eric | Officer, CHIEF BUSINESS OFFICER | Open Market Sale | -1,352 | 77.48 | -104,752.96 | -41,9% | |
| 2026-01-07 | Utter Christine Marie | Officer, SVP, CHIEF ACCOUNTING OFFICER | Open Market Sale | -1,235 | 77.45 | -95,650.75 | -38,2% | |
| 2026-01-06 | Utter Christine Marie | Officer, SVP, CHIEF ACCOUNTING OFFICER | Open Market Sale | -1,381 | 76.95 | -106,267.95 | -42,5% | |
| 2026-01-06 | Klein Matthew B. | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -5,149 | 76.95 | -396,215.55 | -158,3% | |
| 2026-01-06 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -54 | 76.95 | -4,155.30 | -1,7% | |
| 2026-01-06 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -1,739 | 76.95 | -133,816.05 | -53,5% | |
| 2026-01-06 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -1,279 | 76.95 | -98,419.05 | -39,3% | |
| 2026-01-06 | Pauwels Eric | Officer, CHIEF BUSINESS OFFICER | Open Market Sale | -1,789 | 76.95 | -137,663.55 | -55,0% | |
| 2026-01-06 | Gravier Pierre | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -2,139 | 76.95 | -164,596.05 | -65,8% | |
| 2026-01-06 | Golden Lee Scott | Officer, EVP & CHIEF MEDICAL OFFICER | Open Market Sale | -1,340 | 76.95 | -103,113.00 | -41,2% | |
| 2026-01-05 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -1,035 | 76.10 | -78,763.50 | -31,5% | |
| 2026-01-05 | Reeve Emma | Director | Open Market Sale | -734 | 76.00 | -55,784.00 | -22,3% | |
| 2026-01-05 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -1,123 | 74.92 | -84,135.16 | -33,6% | |
| 2026-01-05 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -108 | 76.79 | -8,293.32 | -3,3% | |
| 2026-01-02 | STEELE GLENN JR MD PHD | Director | Open Market Sale | -12,000 | 76.35 | -916,200.00 | -366,0% | |
| 2025-12-30 | Klein Matthew B. | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -8,089 | 76.64 | -619,940.96 | -247,7% | |
| 2025-12-19 | Pauwels Eric | Officer, CHIEF BUSINESS OFFICER | Open Market Sale | -10,548 | 77.55 | -817,997.40 | -326,8% | |
| 2025-12-19 | Pauwels Eric | Officer, CHIEF BUSINESS OFFICER | Open Market Sale | -4,537 | 76.33 | -346,309.21 | -138,4% | |
| 2025-12-19 | Pauwels Eric | Officer, CHIEF BUSINESS OFFICER | Open Market Sale | -3,220 | 78.33 | -252,222.60 | -100,8% | |
| 2025-12-19 | Pauwels Eric | Officer, CHIEF BUSINESS OFFICER | Open Market Sale | -1,500 | 75.77 | -113,655.00 | -45,4% | |
| 2025-12-19 | Pauwels Eric | Officer, CHIEF BUSINESS OFFICER | Open Market Sale | -313 | 77.73 | -24,329.49 | -9,7% | |
| 2025-12-19 | Pauwels Eric | Officer, CHIEF BUSINESS OFFICER | Open Market Sale | -193 | 75.45 | -14,561.85 | -5,8% | |
| 2025-12-19 | Pauwels Eric | Officer, CHIEF BUSINESS OFFICER | Open Market Sale | -42 | 77.26 | -3,244.92 | -1,3% | |
| 2025-12-19 | Pauwels Eric | Officer, CHIEF BUSINESS OFFICER | Open Market Sale | -59 | 78.01 | -4,602.59 | -1,8% | |
| 2025-12-19 | Pauwels Eric | Officer, CHIEF BUSINESS OFFICER | Open Market Sale | -59 | 78.43 | -4,627.37 | -1,8% | |
| 2025-12-19 | Pauwels Eric | Officer, CHIEF BUSINESS OFFICER | Open Market Sale | -37 | 75.66 | -2,799.42 | -1,1% | |
| 2025-12-18 | Pauwels Eric | Officer, CHIEF BUSINESS OFFICER | Open Market Sale | -120 | 75.02 | -9,002.40 | -3,6% | |
| 2025-12-18 | Pauwels Eric | Officer, CHIEF BUSINESS OFFICER | Open Market Sale | -2,831 | 75.07 | -212,523.17 | -84,9% | |
| 2025-12-18 | Pauwels Eric | Officer, CHIEF BUSINESS OFFICER | Open Market Sale | -251 | 75.00 | -18,825.00 | -7,5% | |
| 2025-12-17 | Pauwels Eric | Officer, CHIEF BUSINESS OFFICER | Open Market Sale | -3,584 | 75.31 | -269,911.04 | -107,8% | |
| 2025-12-17 | Pauwels Eric | Officer, CHIEF BUSINESS OFFICER | Open Market Sale | -35,261 | 75.44 | -2,660,089.84 | -1062,8% | |
| 2025-12-17 | Pauwels Eric | Officer, CHIEF BUSINESS OFFICER | Open Market Sale | -100 | 76.00 | -7,600.00 | -3,0% | |
| 2025-12-17 | Pauwels Eric | Officer, CHIEF BUSINESS OFFICER | Open Market Sale | -1,245 | 75.28 | -93,723.60 | -37,4% | |
| 2025-12-03 | Reeve Emma | Director | Open Market Sale | -733 | 78.62 | -57,628.46 | -23,0% | |
| 2025-12-02 | Klein Matthew B. | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -3,428 | 79.07 | -271,051.96 | -108,3% | |
| 2025-11-25 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -911 | 82.63 | -75,275.93 | -30,1% | |
| 2025-11-25 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -862 | 83.35 | -71,847.70 | -28,7% | |
| 2025-11-25 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -689 | 82.63 | -56,932.07 | -22,7% | |
| 2025-11-25 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -574 | 84.67 | -48,600.58 | -19,4% | |
| 2025-11-25 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -289 | 84.61 | -24,452.29 | -9,8% | |
| 2025-11-25 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -200 | 85.37 | -17,074.00 | -6,8% | |
| 2025-11-25 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -200 | 85.34 | -17,068.00 | -6,8% | |
| 2025-11-25 | Jacobson Allan Steven | Director | Open Market Sale | -700 | 85.32 | -59,724.00 | -23,9% | |
| 2025-11-25 | Jacobson Allan Steven | Director | Open Market Sale | -400 | 85.24 | -34,096.00 | -13,6% | |
| 2025-11-25 | Jacobson Allan Steven | Director | Open Market Sale | -3,502 | 83.38 | -291,996.76 | -116,7% | |
| 2025-11-25 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -180 | 85.17 | -15,330.60 | -6,1% | |
| 2025-11-25 | Jacobson Allan Steven | Director | Open Market Sale | -2,510 | 83.93 | -210,664.30 | -84,2% | |
| 2025-11-25 | Jacobson Allan Steven | Director | Open Market Sale | -2,460 | 82.58 | -203,146.80 | -81,2% | |
| 2025-11-25 | Jacobson Allan Steven | Director | Open Market Sale | -2,264 | 82.63 | -187,074.32 | -74,7% | |
| 2025-11-25 | Jacobson Allan Steven | Director | Open Market Sale | -1,238 | 84.47 | -104,573.86 | -41,8% | |
| 2025-11-25 | Jacobson Allan Steven | Director | Open Market Sale | -1,125 | 84.45 | -95,006.25 | -38,0% | |
| 2025-11-25 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -21,844 | 83.33 | -1,820,260.52 | -727,2% | |
| 2025-11-25 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -13,514 | 82.55 | -1,115,580.70 | -445,7% | |
| 2025-11-25 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -9,171 | 84.42 | -774,215.82 | -309,3% | |
| 2025-11-25 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -4,834 | 83.39 | -403,107.26 | -161,0% | |
| 2025-11-25 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -3,744 | 82.61 | -309,291.84 | -123,6% | |
| 2025-11-25 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -3,663 | 83.41 | -305,530.83 | -122,1% | |
| 2025-11-25 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -3,095 | 85.15 | -263,539.25 | -105,3% | |
| 2025-11-25 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -2,790 | 82.82 | -231,067.80 | -92,3% | |
| 2025-11-25 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -2,621 | 84.54 | -221,579.34 | -88,5% | |
| 2025-11-25 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -1,757 | 84.56 | -148,571.92 | -59,4% | |
| 2025-11-25 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -990 | 83.44 | -82,605.60 | -33,0% | |
| 2025-11-24 | Jacobson Allan Steven | Director | Open Market Sale | -5,701 | 80.13 | -456,821.13 | -182,5% | |
| 2025-11-24 | Jacobson Allan Steven | Director | Open Market Sale | -6,100 | 80.15 | -488,915.00 | -195,3% | |
| 2025-11-24 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -21,206 | 80.19 | -1,700,509.14 | -679,4% | |
| 2025-11-24 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -6,101 | 80.17 | -489,117.17 | -195,4% | |
| 2025-11-24 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -4,715 | 80.15 | -377,907.25 | -151,0% | |
| 2025-11-24 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -1,900 | 80.14 | -152,266.00 | -60,8% | |
| 2025-11-24 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -1,650 | 80.14 | -132,231.00 | -52,8% | |
| 2025-11-21 | Reeve Emma | Director | Open Market Sale | -10,000 | 79.50 | -795,000.00 | -317,6% | |
| 2025-11-17 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -1,843 | 75.64 | -139,404.52 | -55,7% | |
| 2025-11-17 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -777 | 76.53 | -59,463.81 | -23,8% | |
| 2025-11-17 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -192 | 77.18 | -14,818.56 | -5,9% | |
| 2025-11-12 | Reeve Emma | Director | Open Market Sale | -7,333 | 74.50 | -546,308.50 | -218,3% | |
| 2025-10-30 | Reeve Emma | Director | Open Market Sale | -12,000 | 69.50 | -834,000.00 | -333,2% | |
| 2025-10-30 | Reeve Emma | Director | Open Market Sale | -3,666 | 69.50 | -254,787.00 | -101,8% | |
| 2025-10-07 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -1,757 | 62.89 | -110,497.73 | -44,1% | |
| 2025-10-07 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -1,306 | 63.80 | -83,322.80 | -33,3% | |
| 2025-10-07 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -312 | 64.97 | -20,270.64 | -8,1% | |
| 2025-10-06 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -2,266 | 65.07 | -147,448.62 | -58,9% | |
| 2025-10-03 | Reeve Emma | Director | Open Market Sale | -3,149 | 66.11 | -208,180.39 | -83,2% | |
| 2025-10-03 | Jacobson Allan Steven | Director | Open Market Sale | -12,000 | 65.00 | -780,000.00 | -311,6% | |
| 2025-10-03 | Reeve Emma | Director | Open Market Sale | -4,591 | 66.09 | -303,419.19 | -121,2% | |
| 2025-10-03 | Reeve Emma | Director | Open Market Sale | -4,037 | 66.10 | -266,845.70 | -106,6% | |
| 2025-10-03 | Reeve Emma | Director | Open Market Sale | -3,028 | 65.09 | -197,092.52 | -78,7% | |
| 2025-10-03 | Reeve Emma | Director | Open Market Sale | -2,729 | 65.05 | -177,521.45 | -70,9% | |
| 2025-10-03 | Reeve Emma | Director | Open Market Sale | -2,381 | 66.87 | -159,217.47 | -63,6% | |
| 2025-10-03 | Reeve Emma | Director | Open Market Sale | -2,163 | 65.02 | -140,638.26 | -56,2% | |
| 2025-10-03 | Reeve Emma | Director | Open Market Sale | -1,884 | 66.89 | -126,020.76 | -50,3% | |
| 2025-10-03 | Reeve Emma | Director | Open Market Sale | -1,600 | 66.93 | -107,088.00 | -42,8% | |
| 2025-10-03 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -23,863 | 66.45 | -1,585,696.35 | -633,5% | |
| 2025-10-03 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -23,419 | 65.45 | -1,532,773.55 | -612,4% | |
| 2025-10-03 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -4,276 | 67.15 | -287,133.40 | -114,7% | |
| 2025-10-03 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -1,760 | 66.56 | -117,145.60 | -46,8% | |
| 2025-10-03 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -1,609 | 65.46 | -105,325.14 | -42,1% | |
| 2025-10-03 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -73 | 67.16 | -4,902.68 | -2,0% | |
| 2025-10-03 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -7,400 | 66.44 | -491,656.00 | -196,4% | |
| 2025-10-03 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -6,124 | 65.47 | -400,938.28 | -160,2% | |
| 2025-10-03 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -3,100 | 64.43 | -199,733.00 | -79,8% | |
| 2025-10-03 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -1,500 | 67.15 | -100,725.00 | -40,2% | |
| 2025-10-03 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -906 | 66.63 | -60,366.78 | -24,1% | |
| 2025-10-03 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -877 | 66.67 | -58,469.59 | -23,4% | |
| 2025-10-03 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -838 | 65.72 | -55,073.36 | -22,0% | |
| 2025-10-03 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -824 | 65.73 | -54,161.52 | -21,6% | |
| 2025-10-03 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -550 | 64.44 | -35,442.00 | -14,2% | |
| 2025-10-03 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -536 | 64.43 | -34,534.48 | -13,8% | |
| 2025-09-12 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -1,019 | 61.31 | -62,474.89 | -25,0% | |
| 2025-09-12 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -905 | 61.21 | -55,395.05 | -22,1% | |
| 2025-09-12 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -544 | 62.09 | -33,776.96 | -13,5% | |
| 2025-09-12 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -22,117 | 61.33 | -1,356,435.61 | -541,9% | |
| 2025-09-11 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -2,356 | 61.00 | -143,716.00 | -57,4% | |
| 2025-09-11 | Reeve Emma | Director | Open Market Sale | -10,000 | 59.50 | -595,000.00 | -237,7% | |
| 2025-09-11 | Reeve Emma | Director | Open Market Sale | -3,534 | 59.50 | -210,273.00 | -84,0% | |
| 2025-09-11 | Reeve Emma | Director | Open Market Sale | -1,334 | 59.50 | -79,373.00 | -31,7% | |
| 2025-09-11 | Reeve Emma | Director | Open Market Sale | -837 | 59.50 | -49,801.50 | -19,9% | |
| 2025-09-11 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -17,838 | 61.00 | -1,088,118.00 | -434,7% | |
| 2025-09-11 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -2,470 | 61.00 | -150,670.00 | -60,2% | |
| 2025-09-09 | SOUTHWELL DAVID P | Director | Open Market Sale | -12,000 | 58.34 | -700,080.00 | -279,7% | |
| 2025-08-05 | Klein Matthew B. | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -10,739 | 51.74 | -555,635.86 | -222,0% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.